ConserV Bioscience to develop ‘broad-spectrum’ coronavirus vaccine
UK biotech company ConserV Bioscience will collaborate on the development of a broad-spectrum coronavirus vaccine with Lawrence Livermore National Laboratory (LLNL).
The vaccine has been designed to enable broad-spectrum protection against coronavirus pathogens originating from humans and animals, including MERS, SARS and SARS-CoV-2.
The vaccine candidate consists of conserved immunoreactive regions from external and internal coronavirus proteins encoded in messenger RNA (mRNA).
LLNL will use its proprietary nanolipoprotein particle (NLP) technology to formulate the mRNA constructs prior to injections.
This will allow for the freeze drying of both components of the vaccine separately, with the aim of improving storage and transport conditions compared to other mRNA vaccine products.
Read more: http://www.pharmatimes.com/news/conserv_bioscience_to_develop_broad-spectrum_coronavirus_vaccine_1361587
The vaccine has been designed to enable broad-spectrum protection against coronavirus pathogens originating from humans and animals, including MERS, SARS and SARS-CoV-2.
The vaccine candidate consists of conserved immunoreactive regions from external and internal coronavirus proteins encoded in messenger RNA (mRNA).
LLNL will use its proprietary nanolipoprotein particle (NLP) technology to formulate the mRNA constructs prior to injections.
This will allow for the freeze drying of both components of the vaccine separately, with the aim of improving storage and transport conditions compared to other mRNA vaccine products.
Read more: http://www.pharmatimes.com/news/conserv_bioscience_to_develop_broad-spectrum_coronavirus_vaccine_1361587
